Status:
COMPLETED
Effectiveness of a Valsartan Based vs an Amlodipine Based Treatment Strategy in naïve Patients With Stage 1 or Stage 2 Hypertension or in Patients Uncontrolled on Current Monotherapy
Lead Sponsor:
Novartis
Conditions:
Hypertension
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
Essential hypertension is a widespread disease which affects one out of every three adults in the industrialized world. It contributes to cardiovascular disease development, a major and well establish...
Eligibility Criteria
Inclusion
- Inclusion criteria
- MSSBP\> 140 mm Hg, and/or MSDBP\> 90 mm Hg and currently treated with either valsartan 320 mg/ HCTZ 25 mg or amlodipine 10 mg/HCTZ 25 mg at end of core study
- Exclusion criteria
- Premature discontinuation in the core study or failure to comply with the core study protocol
- Any patient that the investigator decides should not participate in the extension
- Other protocol-defined inclusion/exclusion criteria may apply
Exclusion
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2007
Estimated Enrollment :
79 Patients enrolled
Trial Details
Trial ID
NCT00351130
Start Date
June 1 2006
End Date
March 1 2007
Last Update
February 24 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigative Centers, Germany
2
Novartis Pharmaceuticals
Basel, Switzerland